Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-626-4 | CAS number: 7659-86-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study according to generally accepted scientific standards but no information on test substance purity was reported..
- Objective of study:
- absorption
- distribution
- excretion
- metabolism
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- The metabolism of 2-ethylhexyl thioglycolate was studied in rats. 3 young male received by gavage 80 mg of 35S marked 2-ethylhexyl thioglycolate. Faeces and urine were analysed every 24 hours. After 3 days observation, liver, kidney, spleen, brain, musculature, heart, lungs, serum, adrenals, hypophyse and thymus were sampled. The radioactivity of the extracts, solutions and residues was quantitatively measured. The qualitative measure of individual samples was done with thin layer chromatography. There was no data whether control test was performed.
- GLP compliance:
- no
- Radiolabelling:
- yes
- Remarks:
- 35S
- Species:
- rat
- Strain:
- not specified
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: young
- Weight at study initiation: mean bodyweight: 200g
- Individual metabolism cage: yes
- Diet (e.g. ad libitum): Pellet food ad libitum
- Water (e.g. ad libitum): ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): no data
- Humidity (%): no data
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): no data - Route of administration:
- oral: gavage
- Vehicle:
- other: sunflower oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE
- Justification for use and choice of vehicle (if other than water): no data
- Concentration in vehicle: 160 g/L
- Amount of vehicle (if gavage): 0.5 mL
- Lot/batch no. (if required): no data
- Purity: no data
HOMOGENEITY AND STABILITY OF TEST MATERIAL: no data - Duration and frequency of treatment / exposure:
- 1 treatment
- Dose / conc.:
- 80 other: mg
- No. of animals per sex per dose / concentration:
- 3
- Control animals:
- not specified
- Positive control reference chemical:
- not needed
- Details on study design:
- - Dose selection rationale: literature data
- Details on dosing and sampling:
- PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled : liver, kidney, spleen, brain, muscle, heart, lungs, serum, adrenals, hypophyse and thymus were observed, and feces and urine
- Time and frequency of sampling: Liver, kidney, splenn, brain, musculature, heart, lungs, serum, adrenals, hypophyse and thymus after 3 days, feces and urine: every 24 hours
METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled : Liver, kidney, splenn, brain, musculature, heart, lungs, serum, adrenals, hypophyse and thymus were observed as well as faeces and urine
- Time and frequency of sampling: liver, kidney, splenn, brain, musculature, heart, lungs, serum, adrenals, hypophyse and thymus after 3 days, faeces and urine: every 24 hours
- From how many animals: 3
- Method type(s) for identification : Liquid scintillation counting, TLC
- Limits of detection and quantification: no data
TREATMENT FOR CLEAVAGE OF CONJUGATES (if applicable): - Statistics:
- no data
- Preliminary studies:
- Not conducted.
- Type:
- excretion
- Results:
- After 3 days, faeces excretion reaches 7.3 % of used activity and urine excretion reaches 73.0 %
- Type:
- absorption
- Results:
- The substance is well absorbed but remains not in the organs
- Type:
- distribution
- Results:
- No major site of accumulation (regarding concentration per g tissue) could be defined
- Type:
- metabolism
- Results:
- The intact substance was neither found in excrements nor in organs
- Details on excretion:
- After 3 days, faeces excretion reaches 7.3 % of used activity and urine excretion reaches 73.0 % . Total amount of secreted radioactivity after 3 days is 80.3%. (See table 1 for further details).
It was assumed that a part of the glycol acid was metabolised to CO2 and expired. - Metabolites identified:
- yes
- Details on metabolites:
- Sulphur containing and ninhydrin positive metabolism products were found in all organs and excrements.
- Conclusions:
- No bioaccumulation potential based on study results
The substance is well absorbed. No major site of accumulation (regarding concentration per g tissue) could be defined.
The intact substance was neither found in excrements nor in organs.
After 3 days, faeces excretion reaches 7.3 % of used radioactivity and urine excretion reaches 73.0 % .
Sulphur containing and ninhydrin positive metabolism products (linked to amino acids and peptides products) were found in all organs and excrements. - Executive summary:
In a metabolism study, 3 male rats (weight 200 g, strain unspecified) were given a single oral dose of 80 mg35S-thioglycolic acid 2-ethylhexyl ester (70 µCi)/rat (Seidler et al., 1971). They were then housed singly in metabolism cages for 3 days and their faeces and urine were collected over 24-hour periods in each case. Faeces and urine were analyzed every 24 hours. After 3 days observation, liver, kidney, spleen, brain, musculature, heart, lungs, serum, adrenals, hypophyse and thymus were sampled. The radioactivity of the extracts, solutions and residues was quantitatively measured. The qualitative measure of individual samples was done with thin layer chromatography. 2-EHTG is well absorbed by oral administration. On the first day, 67.8% of the administered radioactivity was eliminated in the urine and 3.9% in the faeces. A total of 80.3% of the administered radioactivity was excreted in the urine and faeces within 3 days. Only small amounts of radioactivity accumulated in the organs (adrenals, pituitary < 0.0001%, thymus 0.0002%, values for other organs not specified). The intact substance was neither found in excrements nor in organs. Thioglycolic acid 2-ethylhexyl ester was almost completely metabolized and excreted in the form of sulfur-containing and/or ninhydrin-positive (linked to amino acids and peptides products) metabolites, which were detectable by thin layer chromatography. 2-EHTG is expected to be initially hydrolysed in several tissues by carboxylesterases to thioglycolic acid and the corresponding alcohol (2-ethylhexanol).
Reference
Table 1: Mean values of excretion of 35S activity throughout the study period
% activity |
|
Faeces 1stday |
3.9 +/- 0.02 |
Faeces 2ndday |
2.8+/- 0.02 |
Faeces 3rdday |
0.6+/- 0.01 |
Total accumulated in faeces |
7.3 |
Urine 1stday |
67.8+/- 0.01 |
Urine 2ndday |
2.2+/- 0.01 |
Urine 3rdday |
3.0+/- 0.01 |
Total accumulated in urines |
73.0 |
Total excredet for 3 days |
80.3 |
Table 2: Proportion of 35S activity to the chloroform exctract (=1) of water phase and solid residue
Chloroform extract |
Water phase |
Solid residue |
|
Faeces 1stday |
1 |
0.2 |
3.9 |
Faeces 2ndday |
1 |
0.1 |
0.8 |
Faeces 3rdday |
1 |
0.7 |
0.7 |
Urine 1stday |
1 |
725 |
- |
Urine 2ndday |
1 |
113 |
- |
Urine 3rdday |
1 |
2000 |
- |
Liver |
1 |
9.7 |
0.0 |
Kidney |
1 |
7.0 |
47 |
Spleen |
1 |
41.5 |
0.0 |
Brain |
1 |
3.3 |
45 |
Musculature |
1 |
3.0 |
0.0 |
Heart |
1 |
8.5 |
1.0 |
Lungs |
1 |
4.5 |
19.0 |
Serum |
1 |
112 |
0.0 |
Thymus |
1 |
4.8 |
0.0 |
Table 3 : Summary of the TLC separation products and 35S-wearing metabolism product revealed by autoradiography after incorporation of TGE+.
Hexane Acetic Acid |
Propanol water |
|||
TGE |
Sulphur positive |
Amino acid positive |
Amino acid negative |
|
Liver |
||||
CHCl3- extract |
- |
1 |
n.a. |
n.a. |
Water phase |
- |
1 |
2 |
- |
Residue |
- |
2 |
- |
- |
Kidney |
||||
CHCl3- extract |
- |
1 |
n.a. |
n.a. |
Water phase |
- |
1 |
2 |
- |
Residue |
- |
1 |
2 |
- |
Spleen |
||||
CHCl3- extract |
- |
1 |
n.a. |
n.a. |
Water phase |
- |
1 |
1 |
- |
Residue |
- |
2 |
1 |
- |
Lungs |
||||
CHCl3- extract |
- |
1 |
n.a. |
n.a. |
Water phase |
- |
1 |
2 |
- |
Residue |
- |
1 |
1 |
- |
Faces |
||||
CHCl3- extract |
- |
- |
n.a. |
n.a. |
Water phase |
- |
1 |
3 |
2 |
Residue |
- |
1 |
- |
1 |
Urine |
||||
CHCl3- extract |
- |
2 |
n.a. |
n.a. |
Water phase |
- |
1 |
1 |
5 |
Description of key information
The hydrolysis of 2-ethylhexyl mercaptoacetate (2-EHTG) in aqueous solutions was determined at pH 1.2 and 37°C to simulate the gastric hydrolysis (Groult, 2013). The determination was carried out according to the OECD Guideline No. 111 using a Gas Liquid Chromatography with Flame Ionization Detection (FID) analytical method. 2-EHTG was considered as hydrolytically unstable, the t½ was 6.8 h.
In a metabolism study, 3 male rats (weight 200 g, strain unspecified) were given a single oral dose of 80 mg35S-thioglycolic acid 2-ethylhexyl ester (70 µCi)/rat (Seidler et al., 1971). They were then housed singly in metabolism cages for 3 days and their faeces and urine were collected over 24-hour periods in each case. Faeces and urine were analyzed every 24 hours. After 3 days observation, liver, kidney, spleen, brain, musculature, heart, lungs, serum, adrenals, hypophyse and thymus were sampled. The radioactivity of the extracts, solutions and residues was quantitatively measured. The qualitative measure of individual samples was done with thin layer chromatography. 2-EHTG is well absorbed by oral administration. On the first day, 67.8% of the administered radioactivity was eliminated in the urine and 3.9% in the faeces. A total of 80.3% of the administered radioactivity was excreted in the urine and faeces within 3 days. Only small amounts of radioactivity accumulated in the organs (adrenals, pituitary < 0.0001%, thymus 0.0002%, values for other organs not specified). The intact substance was neither found in excrements nor in organs. Thioglycolic acid 2-ethylhexyl ester was almost completely metabolized and excreted in the form of sulfur-containing and/or ninhydrin-positive (linked to amino acids and peptides products) metabolites, which were detectable by thin layer chromatography. 2-EHTG is expected to be initially hydrolysed in several tissues by carboxylesterases to thioglycolic acid and the corresponding alcohol (2-ethylhexanol).
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - inhalation (%):
- 100
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.